REPROGO LIMITED
Company number NI668614 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£39,746
Balance sheet as at 2026-03-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2020-03-24
- Employees
- 1 (2026 accounts)
- Registered office
- C/O Qubis, 63 University Road, Belfast, Northern Ireland, BT7 1NF
- Postcode
- BT7 1NF
- Capital
- 98 GBP
- Accounts category
- Micro
Accounts
- Last made up to
- 2026-03-31
- Next due by
- 2027-12-31
- Financial year end
- 31 March
Confirmation statement
- Last statement dated
- 2026-02-23
- Next due by
- 2027-03-09
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 2 current · 2 resigned
Group structure
Controlled by QUBIS LIMITED — since 2020-03-24
From persons-with-significant-control filings on the public register.
Contact details
- Website
- reprogo.co.uk
ReproGo: We treat the cause of vascular diseases not just the symptom. We provide new therapies for incurable conditions and disabilities resulting from the deterioration or loss of blood vessels such as diabetic foot ulcers, pressure wounds (bedsores), venous leg ulcers and other non healing wounds.
Competitors Belfast
-
3. PROAXSIS LTD
This company ranks 14 among research and experimental development on biotechnology in Belfast.
The class of 2020
39%
of the 593 companies in this sector incorporated in 2020 are still active today; 55% have since been dissolved.
A fact about the year, not a forecast for this company.